Skip to content

First case report of adalimumab-induced psoriasis in Crohn’s disease

First case report of adalimumab-induced psoriasis in Crohn's disease 1

PubMed journal article First case report of adalimumab-induced psoriasis in Crohn’s diseas was found in Unbound MEDLINE. Download PubMed App to iPhone, iPad, Android smartphone and tablet. First case report of adalimumab-induced psoriasis in Crohn’s disease. Anti-TNF drugs are used increasingly in several diseases with immune-mediated inflammation, not only in rheumatological conditions, but also in inflammatory bowel disease and psoriasis.

First case report of adalimumab-induced psoriasis in Crohn's disease 2We report a 31-year-old woman with extensive CD and perianal lesions, without response to conventional treatment. First case report of adalimumab-induced psoriasis in Crohn’s disease. To the best of our knowledge, this is the first report of adalimumab-induced corneal infiltrates. Psoriasiform dermatitis in a non-psoriatic patient treated with adalimumab. Palmoplantar pustular psoriasis induced by adalimumab: a case report and literature review.

Case Reports in Dermatological Medicine is a peer-reviewed, open access journal that publishes case reports in all areas of dermatological medicine. To our knowledge this is the first case reported in the literature of PLC associated with etanercept treatment. She had no personal or family history of psoriasis or other skin diseases. We report a case of diffuse psoriasis resulting in extensive alopecia in a 32-year-old man being treated with infliximab for Crohn’s disease. We describe a case of new-onset inflammatory polyarthritis associated with the use of adalimumab in the treatment of Crohn’s disease (CD). To our knowledge, this is the first case report of new-onset inflammatory polyarthritis in a patient treated with adalimumab for Crohn’s disease. Psoriasis induced by anti-tumour necrosis factor therapy.

Infliximab And Adalimumab-induced Psoriasis In Crohn’s Disease: A Paradoxical Side Effect

Anti-tumor necrosis factor (anti-TNF) agents have been successfully used to treat both chronic idiopathic inflammatory bowel disease and other immune-mediated chronic diseases, but they can also induce a wide array of cutaneous reactions, including new-onset psoriasis and alopecia. We report a case of alopecia associated with psoriasiform skin lesions in a patient on adalimumab treatment for Crohn’s disease. Case Summary: A 33-year old female with a history of Crohn’s disease presented with complaints of upper abdominal pain and bilious vomiting. Adverse Drug Reactions; Drug-induced disorders; Adalimumab; Mesalamine; Toxicity. To the authors’ knowledge this is first report detailing this occurrence. In a second case report, a patient had no previous history of liver disease or concomitant risk factors for liver disease and developed sub acute liver failure during therapy with Adalimumab for psoriatic arthritis. Ankylosing spondylitis (AS) is a chronic systemic inflammatory disease of unknown etiology which primarily targets sacroiliac and axial joints. (4) were the first to report lymphoma development after anti-TNF- treatment in 2002. A case of acute myeloid leukemia after adalimumab treatment in psoriatic arthritis. Crohn’s disease patient during treatment with adalimumab after a prolonged treatment with azathioprine and steroids.

Etanercept-induced Pityriasis Lichenoides Chronica In A Patient With Rheumatoid Arthritis